1.Qi M, Xin S. FGF signaling contributes to atherosclerosis by enhancing the inflammatory response in vascular smooth muscle cells. Mol Med Rep. 2019; 20(1):162–70.
2.Liu Y, Chen Y, Tan L, Zhao H, Xiao N. Linc00299/miR–490–3p/AURKA axis regulates cell growth and migration in atherosclerosis. Heart Vessels. 2019; 34(8):1370–80.
3.Song K, Li L, Sun G, Wei Y. MicroRNA–381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase–2. Exp Ther Med. 2018; 15(5):4557–63.
4.Chen J, Cui L, Yuan J, Zhang Y, Sang H. Circular RNA WDR77 target FGF–2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR–124. Biochem Biophys Res Commun. 2017; 494(1–2):126–32.
5.Zheng J, Chen K, Wang H, Chen Z, Xi Y, Yin H et al. SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/beta-Catenin Signaling Pathway. Biomed Res Int. 2018; 2018:4769596.
6.Hou WZ, Chen XL, Wu W, Hang CH. MicroRNA–370–3p inhibits human vascular smooth muscle cell proliferation via targeting KDR/AKT signaling pathway in cerebral aneurysm. Eur Rev Med Pharmacol Sci. 2017; 21(5):1080–7.
7.Peng P, Chen T, Wang Q, Zhang Y, Zheng F, Huang S et al. Decreased miR–218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer. Oncol Res Treat. 2019; 42(4):165–85.
8.Song T, Ma K, Zhao C, Yang J, Liu J. MicroRNA–2053 overexpression inhibits the development and progression of hepatocellular carcinoma. Oncol Lett. 2019; 18(2):2043–9.
9.Huang T, Wang G, Yang L, Peng B, Wen Y, Ding G et al. MiR–186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1. Cancer Biomark. 2017; 21(1):221–8.
10.Su G, Sun G, Liu H, Shu L, Liang Z. Downregulation of miR–34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl–2. Heart Vessels. 2018; 33(10):1185–94.
11.Xu Z, Han Y, Liu J, Jiang F, Hu H, Wang Y et al. MiR–135b–5p and MiR–499a–3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C. Sci Rep. 2015; 5:12276.
12.Lin B, Feng DG, Wang F, Wang JX, Xu CG, Zhao H et al. MiR–365 participates in coronary atherosclerosis through regulating IL–6. Eur Rev Med Pharmacol Sci. 2016; 20(24):5186–92.
13.Tong KL, Mahmood Zuhdi AS, Wan Ahmad WA, Vanhoutte PM, de Magalhaes JP, Mustafa MR et al. Circulating MicroRNAs in Young Patients with Acute Coronary Syndrome. Int J Mol Sci. 2018; 19(5).
14.Zhao X, Jia Y, Chen H, Yao H, Guo W. Plasma-derived exosomal miR–183 associates with protein kinase activity and may serve as a novel predictive biomarker of myocardial ischemic injury. Exp Ther Med. 2019; 18(1):179–87.
15.Cornelissen A, Guo L, Sakamoto A, Virmani R, Finn AV. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine. 2019.
16.Saucier D, Wajnberg G, Roy J, Beauregard AP, Chacko S, Crapoulet N et al. Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res. 2019; 1708:100–8.
17.Huang YQ, Li J, Chen JY, Zhou YL, Cai AP, Huang C et al. The Association of Circulating MiR–29b and Interleukin–6 with Subclinical Atherosclerosis. Cell Physiol Biochem. 2017; 44(4):1537–44.
18.Cheng Y, Xiang G, Meng Y, Dong R. MiRNA–183–5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4. Reprod Biol. 2016; 16(3):225–33.
19.Meerson A, Najjar A, Saad E, Sbeit W, Barhoum M, Assy N. Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients. Noncoding RNA. 2019; 5(2).
20.Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid Intima-Media Thickness for Atherosclerosis. J Atheroscler Thromb. 2016; 23(1):18–31.
21.Ridker PM. From C-Reactive Protein to Interleukin–6 to Interleukin–1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016; 118(1):145–56.
22.Gao J, Yang S, Wang K, Zhong Q, Ma A, Pan X. Plasma miR–126 and miR–143 as Potential Novel Biomarkers for Cerebral Atherosclerosis. J Stroke Cerebrovasc Dis. 2019; 28(1):38–43.
23.Wang H, Ma Z, Liu X, Zhang C, Hu Y, Ding L et al. MiR–183–5p is required for non-small cell lung cancer progression by repressing PTEN. Biomed Pharmacother. 2019; 111:1103–11.
24.Miao F, Zhu J, Chen Y, Tang N, Wang X, Li X. MicroRNA–183–5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett. 2016; 11(1):134–40.
25.Waseem M, Ahmad MK, Serajuddin M, Bhaskar V, Sankhwar SN, Mahdi AA. MicroRNA–183–5p: A New Potential Marker for Prostate Cancer. Indian J Clin Biochem. 2019; 34(2):207–12.
26.Xiao Y, Du YY, Gao C, Kong W. [Dynamic alteration of microRNA in high phosphorus induced calcification of vascular smooth muscle cell]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016; 48(5):756–65.